Megan Molteni, WIRED, 06 June 2018, https://www.wired.com/story/crispr-fans-fight-for-egalitarian-access-to-gene-editing/
Now in its second year, CrisprCon provides a platform for ethical discussion, big picture problems, and moral quagmires. This year attendees discussed how the cost of CRISPR may work to perpetuate income inequality, with some speakers discussing the eugenic potential. One panel that provided a few more solutions than answers was the ecotechnologies panel composed of individuals using CRISPR to control or eliminate species. This group discussed how the issue of consent was being worked out in different countries around the world.
Sarah Zhang, The Atlantic, 07 June 2018, https://www.theatlantic.com/science/archive/2018/06/a-crispr-pioneer-on-gene-editing-we-shouldnt-screw-it-up/561932/
Feng Zhang recently took a break from CrisprCon to talk with The Atlantic about his journey with CRISPR and where it could be going. Zhang states that many people email him wanting to know if the technology can help cure themselves or a loved one, and while he understands their position, he cautions that we shouldn’t screw up this opportunity by rushing the technology.
Katy Liszewski, GEN, 15 April 2018, https://www.genengnews.com/gen-articles/true-crispr-a-genetic-genre-with-novel-twists/6296
Staying on top of new CRISPR developments can be simple as attending conferences. However, as that is not feasible for everyone, GEN has summarized the findings presented at the Precision CRISPR Congress. This article covers updates in multiplexing, nanocarriers, plant breeding, and T-cell therapies.
GenomeWeb, 17 April 2018, https://www.genomeweb.com/cell-biology-research/researchers-identify-essential-genes-pluripotent-stem-cells-through-crispr#.WtpCdMgvzcs
Researchers in Jerusalem, Israel, used haploid human pluripotent stem cells and a CRISPR/Cas screen to identify essential and growth-restriction genes. The researchers found that most of the essential genes were nuclear and mitochondrial in function. They hope that publication of this library will reveal key aspects of cellular essentiality.
Diana Kwon, 02 April 2018, The Scientist, https://www.the-scientist.com/?articles.view/articleNo/52209/title/USDA-Will-Not-Regulate-CRISPR-Edited-Crops/
In a statement released on March 28 the USDA stated that they will not regulate plants that have been modified through genome editing as long as the same genotype could have been produced through traditional breeding methods. This announcement has the potential to shave tens of millions of dollars off the cost of crop develop.
Megan Molteni, Wired Science, 02 April 2018 https://www.wired.com/story/a-flawed-study-shows-how-little-we-understand-crisprs-effects/
CRISPR has shown great promise as a therapeutic, but off-target effects remain a concern. Last May a small case study determined that CRISPR therapeutics may lead to dangerous levels off off-target mutations, resulting in the shares of CRISPR startups plummeting. Due to the inability of other scientists to reproduce this work, Nature Methods has retracted the paper. This episode reveals is a genuine lack of knowledge on how CRISPR acts in cells and how many off-target effects are actually introduced. Scientists have been working to answer these questions and develop technology to screen for off-target mutations, but to date not enough research has been completed to fully answer these questions.
Christie Rizk, GenomeWeb, 23 March 2018, https://www.genomeweb.com/gene-silencinggene-editing/crispr-startup-arbor-biotechnologies-salk-institute-concurrently-discover#.WrVUlKjwaUk
Startup Arbor Biotechnologies and the Salk Institute simultaneously published the discovery of a new class 2 enzyme dubbed Cas13d. This new Cas system is smaller than previous Cas13 proteins and uses a single RNA guide, possibly providing for its potential development into a simpler system than the more well-known Cas9. More research into specificity and off-target rates are needed before Cas13d is ready for widespread adoption.
Kristen V Brown, Gizmodo, 05 March 2018, https://gizmodo.com/after-a-few-hiccups-all-bets-are-on-crispr-again-1823521006
In 2017, a publication raised the alarm over potential off-target effects during CRISPR therapies. Multiple research groups set out to reproduce the study and found that the off-target effects initially reported were over-stated. These new studies have worked to restore confidence that the CRISPR gene editing technology may be suitable for gene therapies.
EurekaAlert! 8 March 2018, https://www.eurekalert.org/pub_releases/2018-03/p-cts030218.php
A new study in PLOS Pathogens demonstrates that CRISPR knockout of FREP1 in Anopheles gambiae mosquitos suppressed Plasmodium parasites infections. This could potentially be used as a gene drive mechanism to eliminate malaria infections. The inactivation of FREP1 did result in reduced blood-feeding, lower egg hatching rate, slowed development, and reduced longevity after feeding on blood, raising concerns that the modified mosquito may not be able to compete with its wild-type counterparts.
Alice Park, Time Magazine, 15 February 2018, http://time.com/5159889/why-pig-organs-could-be-the-future-of-transplants/
Due to limited amounts of viable donated organs, thousands of people die each year in the US waiting for a transplant. Scientists have long desired to find a viable replacement for donated human organs and may have one in CRISPR modified pig organs. Pig organs are roughly the same size and shape as human organs, however the presence of viruses in the pig genome have proven a significant barrier to use in clinical settings. Now a company founded by George Church has used CRISPR to inactivate these viruses and generated 15 pigs that could be viable stocks for kidney, liver, lungs, or pancreas transplants.